NEW YORK – Create Medicines has started clinically testing an in vivo CAR therapy that comprises a cancer-killing medley of T, NK, and myeloid cells.

The European Commission will now consider the committee's positive opinions as it determines whether to grant marketing authorization to the drugs.

The firm said the CHMP would not support the application due to concerns about the control arm used in the Phase III PSMAfore trial.

Regeneron's Otarmeni is the first gene therapy approved for OTOF-related hearing loss, which the firm said it will provide to ...

Company execs still have high hopes for the SERD giredestrant, despite a recent trial failure in first-line metastatic breast ...

Four of nine patients responded to the mesothelin-directed therapy, which uses a multi-chain receptor borrowed from NK cells, ...

Researchers at AACR described the development of a classifier that identified a proportion of tumor samples with HRD that did not have BRCA1/2 mutations.

The firm is hoping to show that ODM-212 has anti-tumor activity and can prevent treatment resistance across multiple cancer indications.

Maze intends to use the net proceeds to advance its lead candidates, kidney disease treatments that mimic the protective effects of genetic variants.

SAN DIEGO – While oncologists may not yet be entirely comfortable using next-generation artificial intelligence tools to guide precision treatment decisions, data presented at a medical conference ...

NEW YORK – The European Commission has granted conditional marketing authorization to Ojemda (tovorafenib) for treating BRAF-altered pediatric low-grade glioma. Ipsen licensed rights to Ojemda outside ...

NEW YORK – Ray Therapeutics has raised $125 million in a Series B funding round, which it plans to put toward advancing a pipeline of treatments for patients with severe vision issues — including ...